NCT00308620View on ClinicalTrials.gov

Investigating the Anti-Human Immunodeficiency Virus (HIV) & Anti-inflammatory Effect of Chloroquine

PHASE2/PHASE3TerminatedINTERVENTIONAL
Enrollment

13

Participants

Timeline

Start Date

March 31, 2006

Primary Completion Date

December 31, 2008

Study Completion Date

June 30, 2009

Conditions
HIV Infections
Interventions
DRUG

chloroquine phosphate

250mg or 500mg PO (by mouth) QDay

DRUG

Placebo

Placebo once daily for 8 weeks

Trial Locations (1)

55455

Minnesota ACTU, Minneapolis

Sponsors
All Listed Sponsors
collaborator

Minnesota Medical Foundation

OTHER

lead

University of Minnesota

OTHER